Table 1.
Patient demographics, co-morbidities and characteristics.
| Group N |
Stable 45 |
Decompensated 46 |
Significance |
|---|---|---|---|
| Age, years (95% CI) | 56.1 (51.8—60.4) | 60.7 (57.1—64.3) | 0.11 |
| Gender: Female | 20 (44.4) | 20 (43.5) | 0.93 |
| Male | 25 (55.6) | 26 (56.5) | |
| African-American | 29 (64.4) | 39 (84.5) | 0.08 |
| White | 14 (31.1) | 6 (13.4) | |
| Hispanic | 2 (0.02) | 1 (2.1) | |
| Diabetes | 13 (28.9%) | 14 (30.4%) | 0.87 |
| Hypertension | 38 (84.4%) | 46 (100%) | <0.01* |
| High Cholesterol | 21 (46.7%) | 31 (67.4%) | 0.05 |
| Coronary Artery Disease | 23 (51.1%) | 32 (69.6%) | 0.07 |
| Hemoglobin, g/dL (95% CI) | 13.0 (12.6—13.5) | 12.5 (12.0—13.0) | 0.08 |
| EF, % (95% CI) | 35.3 (30.4—40.1) | 30.7 (26.2—35.2) | 0.17 |
| HF Etiology: Preserved | 15 (33.3%) | 8 (17.4%) | 0.05 |
| Reduced | 30 (66.7%) | 38 (82.6%) | |
|
Mean Arterial Pressure, mmHg
(95% CI) |
90.3 (85.7—94.9) | Pre-Tx: 110.4 (102.6—118.2)) Post- Tx: 96.7 (90.8—101.8) |
<0.01* <0.01* |
| Diuresis | 40 (88.9) | 43 (93.4) | 0.46 |
| Nitrates | 31 (68.9) | 27 (58.7) | 0.18 |
| Sublingual/PO | 45 (100) | 3 (11.1) | |
| Percutaneous | - | 18 (66.7) | |
| Intravenous | - | 6 (22.2) | |
| Inotropes | 1 (2.2) | 9 (19.6) | <0.01* |
| Dobutamine | 1 (100) | 3 (33.3) | |
| Nesiritide | - | 6 (66.6) |
*
denotes p < 0.05